BioLineRx Soars on Pancreatic Cancer Trial Buzz: What’s Driving the Surge?
The Big News Shaking Up BLRX BioLineRx (NASDAQ: BLRX), a scrappy biopharmaceutical player out of Israel, is stealing the spotlight today, and for good reason. The company just dropped a bombshell announcement: new data from the pilot phase of its CheMo4METPANC Phase 2 trial for pancreatic cancer is headed to the American Society of Clinical … Read more